Developing Novel Precision Medicine for Glioblastoma

Glioblastoma (GBM) demonstrates some of the worst survival outcomes, likely due to poor clinical predictive information and limited treatment options. We have developed a clinical test for adult GBM that can predict the risk of tumor advancement based on the activity of the patient’s own genes. Our goal is to investigate if this clinical test can be applied to pediatric GBM tumors to not only provide accurate predictive information, but potentially identify new treatment avenues for patients that need it.